CHARLOTTESVILLE, Va. & TORONTO--(BUSINESS WIRE)--Functional Neuromodulation, Ltd. has completed enrollment in the ADvance Study. Forty-two North American patients with mild Alzheimer’s have had a deep brain stimulation (DBS) system implanted in this study to evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain’s memory circuit. The ADvance Study is the only double-blind randomized and controlled trial and the largest study ever conducted of DBS for Alzheimer’s. Top-line outcomes data are expected in the second quarter of 2015.
Help employers find you! Check out all the jobs and post your resume.